Protagonist Therapeutics (PTGX) risk factors, FY2025 10-K

Risks Related to Clinical Development

1. 01We are heavily dependent on the success of our product candidates in clinical development, and if any of these products fail to receive regulatory approval or are not successfully commercialized, our business would be adversely affected49% rewritten
2. 02We are a biopharmaceutical company with no approved products and no historical commercial revenue, which makes it difficult to assess our future prospects and financial results24% rewritten
3. 03Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Clinical failure can occur at any stage of clinical development41% rewritten
4. 04If we are unable to discover and develop new product candidates, our business will be adversely affected
5. 05Our proprietary technology platform may not result in any products of commercial value
6. 06Our product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent their regulatory approval, restrict their approved labeling, or otherwise limit their commercial opportunity
7. 07We have focused our limited resources to pursue particular product candidates and indications, and consequently, we may fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success

Risks Related to our Financial Position and Capital Requirements

1. 08We have incurred a cumulative net loss since our inception and we may incur significant losses in the future. We have never generated any revenue from product sales58% rewritten
2. 09We may require additional funding, which may not be available to us on acceptable terms, or at all26% rewritten
3. 10If we require additional capital, there may be dilution to our existing stockholders, our operations may be restricted, or we may be required to relinquish rights to our product candidates or technologies

Risks Related to our Reliance on Third Parties

1. 11If JNJ does not elect to continue the development of or successfully commercialize Icotyde, or if Takeda does not elect to commercialize rusfertide, our business and business prospects would be adversely affected56% rewritten
2. 12We may have disagreements with JNJ during the term of the JNJ License and Collaboration Agreement or Takeda under the Takeda Collaboration Agreement, and if they are not settled amicably or in the favor of Protagonist, the result may harm our business46% rewritten
3. 13Our current and future development and commercialization collaborations may not be successful
4. 14We face a variety of manufacturing risks and rely on third parties to manufacture our drug substance and clinical drug product and we intend to rely on third parties to produce commercial supplies of any approved product candidate
5. 15Potential business combinations or other strategic transactions may disrupt our business or divert management’s attentionNew

Risks Related to Regulatory Process and Other Legal Compliance Matters

1. 16The regulatory approval processes of the FDA and comparable foreign authorities are lengthy and time consuming, and if we or our collaborators are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed73% rewritten
2. 17and it is possible that none of our existing product candidates or any product candidates we have in development or may seek to develop in the future will ever obtain regulatory approvalNew
3. 18Disruptions at the FDA and other government agencies could negatively affect the review of our regulatory submissions, which could negatively impact our businessNew
4. 19We may fail to obtain additional orphan drug designations from the FDA and/or the EMA for our product candidates, as applicable, and even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity

Risks Related to Commercialization of our Product Candidates

1. 20Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain
2. 21Pharmaceutical and biological product marketing is subject to substantial regulation in the U.S. and EU, and any failure by us or our future commercial and collaborative partners to comply with applicable statutes or regulations can adversely affect our business
3. 22The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs68% rewritten
4. 23We or our collaborators may fail or elect not to commercialize our product candidates, even if approved36% rewritten
5. 24The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors and others in the medical community
6. 25materially adversely affect our financial condition and results of operations87% rewritten

Risks Related to our Business and Industry

1. 26We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we or our collaborators fail to compete effectively
2. 27Outbreaks of disease, epidemics and pandemics have and could continue to adversely impact our business, including our ongoing and planned clinical trials and pre-clinical and discovery research
3. 28Unstable market and macroeconomic conditions, including tariffs or trade policy, may have serious adverse consequences on our business, financial condition and stock price30% rewritten
4. 29We maintain our cash at financial institutions, often in balances that exceed federally insured limits. The failure of financial institutions could adversely affect our ability to pay our operational expenses or make other payments
5. 30Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
6. 31We expect to expand the size of our organization in the future, and we may experience difficulties in managing this growth
7. 32Significant disruptions of information technology systems or cybersecurity incidents could adversely affect our business38% rewritten
8. 33If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
9. 34Our employees, independent contractors, principal investigators, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business
10. 35If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates
11. 36The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to generate revenue

Risks Related to our Intellectual Property

1. 37If we are unable to obtain or protect intellectual property rights related to our product candidates and technologies, we may not be able to compete effectively in our markets24% rewritten
2. 38market. If we are unable to protect the confidentiality of our trade secrets and proprietary know-how or if competitors independently develop viable competing products, our business and competitive position may be harmedNew
3. 39We may be involved in lawsuits and other legal proceedings to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful
4. 40Any issued patents covering our product candidates, including any patent that may issue as a result of our pending or future patent applications, could be found invalid or unenforceable if challenged in court in the United States or abroad22% rewritten
5. 41An adverse outcome in a patent dispute could severely harm our collaborations or cause our collaborators to terminate their respective agreements
6. 42Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts
7. 43We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of former or other employers
8. 44We may be subject to claims challenging the inventorship or ownership of our issued patents, any patents issued as a result of our pending or future patent applications and other intellectual property
9. 45Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
10. 46Intellectual property rights do not necessarily address all potential threats to our business

Risks Related to Ownership of our Common Stock

1. 47Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance31% rewritten
2. 48We are required to develop and maintain proper and effective internal controls over financial reporting and any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock34% rewritten
3. 49Shareholder activism could cause material disruption to our businessNew
4. 50Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management
5. 51Our ability to use net operating loss carryforwards to offset future taxable income, and our ability to use tax credit carryforwards, may be subject to certain limitations
6. 52If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our accruals
7. 53We could be subject to additional tax liabilitiesNew